Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 April 2025
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 February 2025
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2025
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) (TA1029)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 January 2025
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 June 2025
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 August 2025
Suspected sepsis: recognition, diagnosis and early managementStatus:In development | In consultationProgramme:NICE guidelineConsultation end date: 18 July 2025Expected publication date: 19 November 2025
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 December 2025
ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]Status:Topic selectionProgramme:Health technology evaluationExpected publication date: TBC
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Olezarsen for treating familial chylomicronaemia syndrome [TSID11993]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avapritinib for treating moderate to severe symptoms of indolent systemic mastocytosis [ID12202]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC